肝臓
Online ISSN : 1881-3593
Print ISSN : 0451-4203
ISSN-L : 0451-4203
速報
Telaprevir/Peginterferon-alfa2b/Ribavirin併用療法導入直後の腎機能低下機序に関する検討
坂根 貞嗣榊原 祐子由雄 敏之中水流 正一外山 隆石田 永三田 英治
著者情報
ジャーナル フリー

2012 年 53 巻 7 号 p. 434-435

詳細
抄録
Seventeen patients with chronic hepatitis C undergoing telaprevir therapy showed a decrease in the estimated glomerular filtration rate (eGFR), which averaged 77.5 ml/min/1.73 m2 before treatment, by 14.6 ml/min/1.73 m2 on average at day 4. To distinguish between the two main causes of acute renal dysfunction, prerenal mechanism and acute tubular necrosis, we measured the sodium concentration in urine (UNa) and fractional excretion of sodium (FENa). The eGFR decrease showed a significant correlation with UNa and also with FENa. These findings indicate that the prerenal mechanism is responsible for the eGFR decline. As patients with an eGFR drop in the early phase of therapy may have an additional risk of adverse events, renal function should be closely monitored.
著者関連情報
© 2012 一般社団法人 日本肝臓学会
前の記事
feedback
Top